Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      NOT_YET_RECRUITING
      A Phase 1/2 Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
      Description

      This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

      Conditions
      Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification
      Talk to us
      RECRUITING
      Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
      Description

      This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib

      Conditions
      Cancer
      Talk to us